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Background: Interleukin-22 (IL-22), a cytokine with important functions in anti-microbial defense and tissue repair,
has been recently suggested to have beneficial effects in obesity and metabolic syndrome in some but not in other
studies. Here, we re-examined the effects of IL-22 on obesity, insulin resistance, and hepatic glucose metabolism.
Results: Genetic deletion of IL-22 did not affect high-fat-diet (HFD)-induced obesity and insulin resistance. IL-22
transgenic mice with relatively high levels of circulating IL-22 (~600 pg/ml) were completely resistant to Concanavalin
A-induced liver injury but developed the same degree of high fat diet (HFD)-induced obesity, insulin resistance, and
fatty liver as the wild-type littermate controls. Similarly, chronic treatment with recombinant mouse IL-22 (rmIL-22)
protein did not affect HFD-induced obesity and the associated metabolic syndrome. In vivo treatment with a single
dose of rmIL-22 downregulated the hepatic expression of gluconeogenic genes and subsequently inhibited hepatic
gluconeogenesis and reduced blood glucose levels both in HFD-fed and streptozotocin (STZ)-treated mice without
affecting insulin production. In vitro exposure of mouse primary hepatocytes to IL-22 suppressed glucose production
and the expression of gluconeogenic genes. These inhibitory effects were partially reversed by blocking STAT3 or the
AMPK signaling pathway.
Conclusion: Biologically active, high levels of IL-22 do not affect obesity and the associated metabolic syndrome.
Acute treatment with IL-22 inhibits hepatic gluconeogenesis, which is mediated via the activation of STAT3 and AMPK
in hepatocytes.
Keywords: Obesity, Insulin resistance, Hyperglycemia, Cytokine, LiverInterleukin-22 (IL-22) is probably the only cytokine that
is produced by immune cells but does not directly target
immune cells due to lack of IL-22 receptor 1 (IL-22R1)
expression on these cells [1–6]. Instead, IL-22 mainly
targets epithelial cells which express high levels of
IL-22R1 [1–6]. Several types of immune cells have been
reported to produce IL-22. These include Th17 cells,
Th22 cells, activated NK and NKT cells and others [1–6].
The action of IL-22 is mediated via its binding to IL-10R2
and IL-22R1, followed by the activation of signal trans-
ducer and activator of transcription 3 (STAT3) and, to a* Correspondence: bgao@mail.nih.gov
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unless otherwise stated.lesser extent, activation of additional signaling pathways
such as STAT1, STAT5, AKT, ERK, etc. [1–6]. IL-10R2 is
ubiquitously expressed while IL-22R1 is expressed ex-
clusively in epithelial cells (eg. hepatocytes), hepatic stel-
late cells [HSCs], and fibroblasts [1–7]. Accumulating
evidence suggests that IL-22 plays a critical role in anti-
microbial defense and tissue repair in various organs
[1–6]. In the liver, through its action on hepatocytes,
IL-22 has been shown to act as a hepatoprotective factor
that protects against liver injury, fibrosis and steatosis via
the activation of STAT3 in a variety of rodent models and
patients [7–13]. IL-22 does not initiate liver cancer deve-
lopment but can promote proliferation of existing liver
tumor cells via the activation of STAT3 [14–16]. Although
it does not target immune cells, IL-22 may indirectlyis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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chronic viral hepatitis [17].
Numerous recent studies suggest that IL-22 modulates
obesity and its metabolic consequences, but the results
are inconsistent [18–24]. In an early study, injection of
mice with adenovirus expressing IL-22, which produced
super high levels of circulating IL-22, induced marked
body weight loss and thymic atrophy in lean mice [18].
We also observed that IL-22 transgenic mice expressing
super high levels of IL-22 (4000–7000 pg/ml) had much
lower lean body weight [14]. It should be noted that
serum IL-22 levels in healthy individuals and patients
with various types of diseases rarely exceed 200 pg/ml
[15, 25, 26]. Recently, Wang et al. [19] reported that
treatment with high doses of long half-life IL-22Fc pro-
tein (50–100 μg/mouse, half-life t1/2 = 3.02 days, twice a
week for 4 weeks) reduced body weight and ameliorated
hyperglycemia and insulin resistance in obese, leptin
receptor-deficient mice and mice fed a high-fat diet
(HFD). Interestingly, Hasnain et al. [20] reported that
chronic treatment with low doses of short half-life re-
combinant mouse IL-22 protein (rmIL-22)(20 ng/g or
100 ng/g, twice a week for 4 weeks) reduced body
weight and alleviated metabolic complications caused by
HFD in mice. However, Yang et al. [21] found that
chronic treatment with rmIL-22 (300 ng/g, daily for
36 days) ameliorated fatty liver but did not affect body
weight and metabolic parameters in HFD-fed mice. In
contrast, Upadhyay et al. [22] observed that overex-
pression of IL-22 via hydrodynamic injection restored
normal body weight and adiposity in lymphotoxin β
receptor knockout mice. In addition, several studies sug-
gested that T cell-derived IL-22 enhances IL-1β-mediated
inflammation in human adipose tissue and reduces insulin
sensitivity in human hepatocytes, promoting obesity and
diabetes [23, 27].
In the current study, we analyzed the effects of en-
dogenous IL-22 and chronic treatment with rmIL-22 as
well as genetic overexpression of IL-22 on HFD-induced
obesity and metabolic syndrome. Our results indicate
that high circulating levels of transgenically expressed
IL-22, chronic treatment with rmIL-22, or deficiency in
endogenous IL-22 do not affect HFD-induced obesity
and its metabolic consequences in mice. The effect of
IL-22 on glucose metabolism in hepatocytes were also
examined.
Results
Endogenous IL-22 does not play a role in regulating
obesity, insulin resistance, and fatty liver disease
induced by 10 weeks of HFD feeding
It was reported that basal serum levels of IL-22 were ap-
proximately 20 pg/ml in control diet-fed mice, and were
decreased to 5 pg/ml in HFD-fed mice [28]. However, arecent study reported that serum levels of IL-22 were
markedly increased after HFD diet feeding to approxi-
mately 1000 pg/ml compared to approximately 100 pg/ml
in chow-fed mice (Extended data Fig. 1 in reference [19]).
Here we found that serum IL-22 levels were relatively low
(<20 pg/ml) in control- or HFD-fed mice with lower levels
in HFD-fed mice than those in control-fed mice, while
high levels of serum IL-22 were detected in IL-22TG6
mice (~600 pg/ml) (Fig. 1a). HFD feeding did not affect
serum IL-22 levels in IL-22TG6 mice.
To determine the role of IL-22 in obesity and insulin
resistance, we bred IL-22+/− heterozygous mice to gene-
rate wild-type littermates and IL-22KO mice. These
mice were fed a HFD or control diet for 10 weeks. As
illustrated in Fig. 1b, both WT and IL-22KO mice had
similar body weight gain, glucose intolerance, and insu-
lin resistance after 10 weeks of HFD feeding. In addition,
hepatic steatosis as determined by H&E staining and
measurement of hepatic triglyceride levels was compar-
able between HFD-fed WT and IL-22KO mice (data not
shown). This suggests that very low levels of endogenous
IL-22 do not contribute to the pathogenesis of obesity,
insulin resistance, and fatty liver disease in the 10-week
HFD feeding model.
Liver-specific IL-22TG6 mice with relatively high levels of
circulating IL-22 (~600 pg/ml) are resistant to concanavalin
A-induced liver injury but develop the same degree of
HFD-induced obesity, insulin resistance, and fatty liver as
wild-type littermates
The role of IL-22 in regulating obesity and metabolic
syndrome was further examined in IL-22 transgenic
mice, in which IL-22 expression is controlled by albumin
promoter and enhancer [14, 29]. We obtained four lines
of IL-22TG mice, including three lines (IL-22TG8, TG9,
and TG15) that have super high levels of circulating
IL-22 (4000–7000 pg/ml) and one line (IL-22TG6) that
has relatively high levels of circulating IL-22 (~600 pg/ml)
(Fig. 1a) [14, 29]. We have previously demonstrated that
the three lines with super high levels of IL-22 were com-
pletely resistant to Con A-induced liver injury [14]. Here
we report that IL-22TG6 mice were also completely resis-
tant to Concanavalin A-induced liver injury, as demon-
strated by the marked elevation of serum ALT and AST in
WT mice but not in IL-22TG mice (Fig. 2a). Liver his-
tology analysis revealed that WT mice had massive necro-
sis while IL-22TG6 mice only had a few of small necrotic
areas (Fig. 2b). This suggests that high levels of IL-22 in
IL-22TG6 are biologically active.
We have previously found that the IL-22TG8, TG9, and
TG15 mice had much lower lean body weight [14], sug-
gesting that super high IL-22 levels may cause cachexia.
The IL-22TG6 with relatively high levels of circulating
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Fig. 1 Endogenous IL-22 does not play a role in the development of obesity and insulin resistance induced by a HFD. a Two-month old IL-22TG6
mice and their littermate controls were fed a HFD or CD for 10 weeks. Serum IL-22 levels were measured. b, c Two-month old IL-22KO mice and
their littermate controls were fed a HFD or CD for 10 weeks. Body weight was counted weekly (panel b); GTT and ITT were examined after
10 weeks feeding (panel c). CD; control diet; HFD: high-fat diet. Values represent the mean ± SEM (n = 6-12)
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study, HFD-induced obesity and its metabolic conse-
quences were only examined in IL-22TG6 mice. After
HFD feeding, IL-22TG6 mice gained comparable body
weight and had the same total adiposity as WT littermate
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Fig. 2 IL-22TG6 mice with high levels of circulating IL-22 (~600 pm/ml) are
injected with Con A (15 μg/g) for 24 h. a Serum ALT and AST levels were m
treated with Con A for 24 h. Necrotic areas are indicated by dot circles. Valinsulin tolerance test (ITT) analyses revealed that there
were no differences in glucose tolerance or insulin sensi-
tivity between CD- or HFD-fed WT and IL-22TG6 mice
(Fig. 3c-d). Moreover, serum ALT levels, hepatic TG
levels, and hepatic steatosis were also comparable in
HFD-fed WTand IL-22TG6 mice (Fig. 3e-f).     IL-22TG6
                           IL-22TG6
***
resistant to Con A-induced liver injury. WT and IL-22TG mice were
easured. b Representative H&E staining of liver tissues from mice
ues represent the mean ± SEM (n = 10-14). ***P < 0.001
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Fig. 3 IL-22TG6 mice with high levels of circulating IL-22 (~600 pg/ml) develop the same degree of HFD-induced obesity, insulin resistance, and
fatty liver as wild-type littermates. Mice were fed a CD or HFD for 8 weeks. a Body weights were measured. b Total adiposity. c Glucose tolerance
test (GTT). d Insulin resistance test (ITT). e Serum ALT and hepatic TG levels were measured. f Representative H&E staining of liver tissues from
8-week HFD fed mice. Values represent the mean ± SEM (n = 6-14)
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protein does not ameliorate HFD-induced obesity and the
associated metabolic syndrome
In an early study, chronic treatment with rmIL-22 (300 ng/g,
daily injection) (Generon Corporation, Shanghai, China)for 36 days ameliorated fatty liver but did not affect
body weight, fasting glucose, and fasting insulin levels in
HFD-fed mice [21], while a recent study reported that
chronic treatment with low doses of rmIL-22 (R&D
systems) (20 ng/g or 100 ng/g body weight, twice a week)
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mice [20]. One of the reasons for this discrepancy might
be the different sources of rmIL-22 were used.
To further clarify this discrepancy, we treated HFD-fed
mice with rmIL-22 (R&D system) (20 ng/g body weight,
twice a week) for 4 weeks. Our results revealed that such
treatment did not affect body weight and fasting glucose
levels (Fig. 4a-b) and insulin and glucose intolerance
(data not shown).
Administration of a single dose of the rmIL-22 protein
reduces blood glucose levels in HFD-fed and streptozocin
(STZ)-treated mice without affecting blood insulin levels:
IL-22 activates STAT3 in acinar cells but not in islets in
the pancreas
To explore whether pharmacologic doses of rmIL-22
have any acute beneficial metabolic effects, we treated
mice with a single dose of the rmIL-22 protein. Admi-
nistration of a single dose of rmIL-22 (1000 ng/g body
weight) did not significantly affect body weight in mice
fed a HFD or CD (data not shown). However, injection of
a single dose of rmIL-22 significantly decreased fasting
blood glucose levels in mice fed a HFD and decreased
plasma glucose levels in mice fed a CD to a lesser extent
(Fig. 5a).
Next, we tested whether IL-22 also reduces blood glu-
cose levels in a model of type I diabetes induced via STZ
injection. Injection of STZ caused pancreatic islet dam-
age (data not shown) and decreased serum insulin levels
in WT mice (Fig. 5b). Similar pancreatic islet damage
was observed in STZ mice treated with or without IL-22
treatment (data not shown). Moreover, as illustrated in
Fig. 5b-c, injection of a single dose of rmIL-22 did not
affect the pancreas weight nor serum insulin levels in
both vehicle- or STZ-treated groups but markedly re-
duced blood glucose levels in STZ-treated mice.
We and others previously reported that IL-22 treat-
ment protects against cerulean-induced pancreatitis inDays





















Fig. 4 Chronic administration of rmIL-22 protein does not affect body weig
5 months and then injected with rmIL-22 (20 ng/g body weight, i.p. injection
were measured. b Fasting blood glucose levels. Values represent the mean ±mice by targeting pancreatic acinar cells [30, 31].
Interestingly, a recent study reported that IL-22 can
directly target mouse and human pancreatic islet beta
cells [20]. However, immunohistochemistry analyses
revealed strong pSTAT3 staining in acinar cells but
not in islets in the pancreas from IL-22-treated mice
(Fig. 5d).
IL-22 inhibits hepatic gluconeogenesis without affecting
glucose uptake
To explore the mechanisms by which IL-22 reduces blood
glucose levels in HFD-fed mice, we performed an in vivo
glucose turn-over assay and pyruvate tolerance test (PTT),
an assay to determine hepatic gluconeogenesis in vivo.
HFD-fed mice were injected with IL-22 adenovirus or
control adenovirus prior to the glucose turn-over assay.
Injection of Ad-IL-22 resulted in significant elevation of
circulating IL-22 (~5000 pg/ml), and this elevation lasted
for more than two weeks [10]. As illustrated in Fig. 6a, the
glucose turn-over rate and blood glucose levels were
markedly lower in ad-IL-22-treated mice compared with
ad-vector-treated mice. Fig. 6b shows that blood glucose
levels were significantly elevated after injection of pyruvate
in ad-vector-treated mice; however, such elevation was
not observed in ad-IL-22 injected mice, suggesting that
injection of ad-IL-22 blocks hepatic gluconeogenesis.
Indeed, expression of gluconeogenic genes, including
G6Pase, PEPCK, and TORC2 (also known as CRTC2),
was markedly reduced in ad-IL-22-treated mice com-
pared with ad-vector-treated mice (Fig. 6c). In addition,
administration of a single dose of rmIL-22 markedly
suppressed hepatic expression of gluconeogenic genes
(Fig. 6d).
Glucose uptake experiments showed that IL-22 treat-
ment did not affect glucose uptake in the liver, muscle,
and WAT tissues (Fig. 6e). There was a trend towards
an increase in BAT in mice treated with rmIL-22, but it
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Fig. 5 Injection of a single dose of recombinant mouse IL-22 (rmIL-22) protein reduces blood glucose levels in HFD- and streptozotocin (STZ)-treated
mice. a Mice were fed a HFD for 8 weeks and then injected with saline or rmIL-22 for 2 h. Blood glucose levels were detected 120 min post IL-22
injection. b, c C57BL/6 mice were injected with STZ for 5 consecutive days. Twenty eight days later, mice were injected with saline or rmIL-22, and
sacrificed 2 h later. Pancreas weights and insulin levels were measured (panel b). Glucose levels were measured at various time points post rmIL-22
injection (panel c). Values represent the mean ± SEM (n = 10). *P < 0.05 and **P < 0.01 compared with the corresponding saline treated groups.
d C57BL/6 mice were treated with rmIL-22 for 2 h, pancreas tissues were collected for immunostaining with anti-pSTAT3 antibody. Representative
positive pSTAT3 nuclei in acinar cells are indicated by yellow arrows but not in islets (indicated by dotted lines)
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inhibition of hepatic gluconeogenesis in vitro
To further understand the mechanisms underlying IL-22-
mediated inhibition of hepatic gluconeogenesis, we exa-
mined the effects of IL-22 signaling pathways on hepatic
gluconeogenesis and gluconeogenic genes in primary
mouse hepatocytes. As shown in Figs. 7a-b, treatment
with rmIL-22 predominantly induced the phosphorylation
and activation of STAT3 and to a lesser extent induced
pAKT and pAMPK activation in primary mouse hepato-
cytes. Compared to insulin stimulation, rmIL-22 induced
much weaker pAKT activation in primary mouse hepato-
cytes. In addition, rmIL-22 treatment did not further en-
hance insulin activation of pAKT (data not shown).
Next, we investigated whether these signaling path-
ways contributed to the IL-22-mediated inhibition of
glucose production in primary hepatocytes. As shown inFig. 7c, treatment with rmIL-22 decreased basal glucose
production, and expression of gluconeogeneic genes,
including PEPCK, G6Pase, and PGC-1α, in WT he-
patocytes. IL-22 inhibition of glucose production was
completely abolished, whereas IL-22 inhibition of these
genes was partially diminished in STAT3 knockout hepa-
tocytes. Interestingly, treatment with AMPK inhibitor
but not with the PI3 kinase inhibitor LY294002 partially
diminished the IL-22 inhibition of glucose production
and G6Pase gene expression in WT hepatocytes.
Similarly, treatment with rmIL-22 also decreased
Bt2-cAMP-induced glucose production in WT mouse
hepatocytes but not in STAT3 knockout hepatocytes.
Such inhibition was also partially diminished in AMPK
inhibitor-treated hepatocytes but not in PI3 inhibitor-
treated hepatocytes (Fig. 7d). Treatment with rmIL-22
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Fig. 6 IL-22 inhibits hepatic gluconeogenesis without affecting glucose uptake in vivo. a-c Mice were fed a HFD for 8 weeks and then injected
with ad-vector or ad-IL-22 for 5 days. A glucose tracer assay in vivo was performed. Glucose turnover rates and plasma glucose levels are shown
(panel a). A pyruvate tolerance test (PTT) was performed (panel b). Real-time PCR analyses of gluconeogenic genes (panel c). d-e C57BL/6 mice
were fed a HFD for 8 weeks and then fasted for 4 h, followed by treatment with saline or rmIL-22 (1 μg/g) for 2 h. Real-time PCR analyses of gluconeogenic
genes (panel d). Two-deoxyglucose uptake experiments in vivo were performed (panel e). Values represent the mean ± SEM (n=6-10). *P < 0.05,
**P < 0.01, and ***P < 0.001 compared with the corresponding ad-IL-22-treated or rmIL-22-treated groups
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inhibition of PEPCK and G6Pase but not PGC-1α was
partially diminished in STAT3 knockout hepatocytes and
AMPK inhibitor-treated hepatocytes (Fig. 7d).
Discussion
As mentioned in the introduction, the effects of IL-22
on obesity and metabolic syndrome are very controver-
sial. Here, we provide evidence that endogenous IL-22
or biologically active, high circulating levels of IL-22 do
not affect HFD-induced obesity and its metabolic conse-
quences, although IL-22 is able to inhibit hepatic gluco-
neogenesis in hepatocytes.
Endogenous IL-22 does not play a role in modulating
HFD-induced metabolic syndrome
It has been reported that serum levels of IL-22 in mice
are decreased by HFD feeding from approximately
20 pg/ml in lean controls to approximately 5 pg/ml [28].
In our study, serum levels of IL-22 were also relatively
low (<20 pg/ml) in both CD and HFD-fed mice (Fig. 1a).
In addition, we found that IL-22TG6 mice, which have
high circulating levels of IL-22 (~600 pg/ml), develop
the same degree of HFD-induced obesity and its meta-
bolic consequences as wild-type littermates. Thus, the
very low levels of endogenous IL-22 are unlikely to con-
tribute to the pathogenesis of HFD-induced obesity and
its metabolic sequelae. This notion is further supported
by our finding that HFD feeding induced the same de-
gree of body weight gain, obesity, and insulin resistancein WT littermates and IL-22KO mice. Recently, Wang
et al. [19] also reported that HFD feeding induced com-
parable levels of obesity in IL-22KO mice and WT mice,
whereas IL-22R1KO mice were more susceptible to
HFD-induced obesity and insulin resistance. Because
IL-22R1 can combine not only with IL-10R2 to act as a
functional IL-22R complex but can also interact with
IL-20R2 to form a receptor for IL-20 and IL-24 [32], it is
likely that IL-22R1 ligands other than IL-22 may play a
role in ameliorating HFD-induced metabolic syndrome.
Biologically active, high levels of IL-22 do not modulate
HFD-induced obesity and its metabolic consequences
Super high levels of circulating IL-22 (4000–7000 pg/ml)
in IL-22TG8 mice or in mice treated with ad-IL-22
caused marked body weight loss in lean mice [14, 18],
suggesting that super high levels of IL-22 induce cachexia.
At present, the mechanisms underlying IL-22-mediated
cachexia remain unclear. It has been well-documented
that a wide variety of cytokines can induce cachexia after
prolonged production via multiple mechanisms, and these
cytokines include TNF-α, IL-6, leukemia inhibitory factor
(LIF), ciliary neurotrophic factor (CNTF) and interferon-γ
(IFN-γ) [33]. It is likely that super high levels of IL-22 pro-
mote cachexia by using mechanisms similar to those used
by these cytokines such as induction of strong acute phase
response and subsequent chronic inflammation [18, 33].
Although it was reported that IL-22 can indirectly induce
inflammation in chronic liver disease [17], hepatic and
serum levels of IL-6, TNF-α, IL-1β were not elevated in
C
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Fig. 7 Treatment with rmIL-22 protein inhibits gluconeogenesis in primary mouse hepatocytes via STAT3- and AMPK-dependent mechanisms.
a Western blot analyses of IL-22-treated primary mouse hepatocytes. b Western blot analyses of IL-22- or insulin-treated hepatocytes. c Primary
wild-type mouse hepatocytes with pre-treated PI3K or AMPK inhibitors, followed by IL-22 treatment. Primary STAT3KO mouse hepatocytes were
also treated with IL-22. d The same experiments as those in panel C except all cells were pre-treated with Bt2-cAMP. In panels c and d, glucose
production and gene expression were analyzed and normalized to 100 % in hepatocytes without IL-22 treatment in each group. Values represent
the mean ± SEM (n = 4). *P < 0.05, **P < 0.01, and ***P < 0.001 compared with the corresponding hepatocytes without rmIL-22 treatment. #P < 0.05
and ##P < 0.01 compared with the corresponding hepatocytes from vehicle +WT mice with rmIL-22 treatment
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IL-22TG8 mice with super high levels of circulating IL-22
(~6000 pg/ml) (Park et al. unpublished data). This sug-
gests that the cachectic effect of super high levels of IL-22
is not due to upregulation of the cachectic factors such as
IL-6 and TNF-α.
Recently, Wang et al. [19] reported that chronic
treatment of mice with high doses of IL-22Fc protein
(50–100 μg/mouse, twice a week) for 6 weeks markedly
reduced the body weights of HFD-fed mice. IL-22Fc has
a long half-life (t1/2 = 3.02 days) and administration of
high doses of IL-22Fc may result in sustained high levels
of IL-22 in vivo. Although Wang et al. reported that
IL-22Fc treatment reduced fat pad size in HFD-fed mice,
they did not analyze body composition, nor did they
examine the effect of IL-22Fc treatment on body weight
in lean mice, so we can’t rule out the possibility that the
weight-reducing effect of IL-22Fc treatment in HFD-fed
mice was due to cachexia caused by super high levels
of IL-22.In an early study, chronic treatment with rmIL-22
(300 ng/g, daily for 36 days) improved fatty liver but did
not affect body weight and the associated metabolic syn-
drome in HFD-fed mice [21]. This is consistent with our
findings that relatively high levels of IL-22 in IL-22TG6
mice do not affect obesity. Lack of the anti-obesity effects
of high levels of circulating IL-22 (600 pg/ml) in IL-22TG6
mice was very unlikely due to developing hepatic IL-22 re-
sistance because IL-22TG6 mice were completely resistant
to Con A-induced liver injury. Surprisingly, a recent study
reported that chronic treatment with low doses of rmIL-22
markedly ameliorated obesity and metabolic syndrome in
HFD-fed mice [20]; however, these results could not be
reproduced in the present study.
IL-22 regulates lipid and glucose metabolism
Previous studies have revealed that IL-22 ameliorates
fatty liver disease by downregulating hepatic expression
of several lipogenic genes [10, 21]. In the current study,
we have demonstrated that IL-22 also regulates glucose
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genesis. First, injection of adeno-IL-22 inhibited glucose
turn-over rate and gluconeogenesis in the liver. Second,
treatment with rmIL-22 inhibited glucose production in
primary mouse hepatocytes. Finally, treatment with IL-22
markedly reduced the expression of gluconeogenic genes,
including PEPCK and G6Pase, in the liver in vivo and in
hepatocytes in vitro. The STAT3, which is the major
downstream of IL-22 signaling pathway, has been shown
to inhibit hepatic lipogenesis and gluconeogenesis [34],
which is in line with the effect of IL-22 on lipid and glu-
cose metabolism in hepatocytes. In addition to the pre-
dominant activation of STAT3 in hepatocytes, IL-22 also
activates, to a lesser extent, many other signaling pathways
including AKT (as shown in Fig. 7 in this paper, and refe-
rences [1–3]). Both STAT3 and AKT are known to inhibit
hepatic gluconeogenesis [34, 35], but our results suggest
that activation of STAT3 and not that of AKT is involved
in the IL-22 suppression of hepatic gluconeogenesis.
In vitro treatment with rmIL-22 inhibited glucose produc-
tion in primary WT mouse hepatocytes but not in STAT3
knockout hepatocytes. Interestingly, although the effects
of IL-22 on glucose production were completely absent in
STAT3 knockout hepatocytes, its effect on gluconeogenic
gene expression was only partially reduced, suggesting the
involvement of additional signaling pathways in this latter
effects. Despite an important role for AKT in inhibiting
hepatic gluconeogenesis [35], inhibition of PI3/AKT by
the PI3 kinase inhibitor LY294002 did not alter the effects
of IL-22 on glucose production and gluconeogenic gene
expression. The lack of a role for AKT in IL-22 inhibition
of gluconeogenesis may be related to the fact that IL-22
only induced very weak AKT activation in hepatocytes.
In this study, we have demonstrated for the first time
that IL-22 treatment activates AMPK in hepatocytes.
AMPK has been shown to play an important role in
inhibiting hepatic gluconeogenesis [36]. Our findings
that the AMPK inhibitor compound C abolished the
IL-22-mediated inhibition of glucose production and
gluconeogenic gene expression suggest that the acti-
vation of AMPK is also involved in the IL-22-mediated
inhibition of gluconeogenesis in hepatocytes.
IL-22 treatment does not protect against STZ-induced
islet damage and insulin reduction in mice
It is well documented that IL-22R1 is primarily ex-
pressed in epithelial cells, such as acinar cells in the
pancreas [3, 30, 31]. Interestingly, Hasanin et al. recently
reported that pancreatic beta cells express IL-22R1, and
IL-22 administration suppresses ER stress and inflamma-
tion and promotes insulin secretion in beta cells [20].
However, several lines of evidence argue against this no-
tion. First, blood insulin levels were lower in IL-22TG8
mice than in WT mice under HFD or normal chowfeeding (Park et al. unpublished data). Second, administra-
tion of STZ causes beta cell damage and reduces insulin
production, which was not averted by administration of
rmIL-22. Third, STAT3, which is a major downstream sig-
naling molecule activated by IL-22, mediates the cytopro-
tective functions of IL-22 [3]. Injection of IL-22 resulted
in strong pSTAT3 activation in acinar cells but not in beta
cells. This activation in acinar cells contributes to the pro-
tective effects exerted by IL-22 on acinar cells and pan-
creatitis [30, 31]. Although we did not detect STAT3
activation in beta cells from IL-22-treated mice, we can’t
rule out that IL-22 may stimulate the STAT3 pathway at
low levels, which may still have a beneficial effect under
stress conditions, or the unlikely possibility that IL-22 ac-
tivates other signaling pathways in beta cells. Further stu-
dies are needed to clarify the functions of IL-22 in beta
cells in the pancreas.
In summary, our findings suggest that biologically ac-
tive, high levels of IL-22 do not affect obesity and its
metabolic consequence. Super high levels of IL-22 may
cause cachexia and subsequently body weight loss. IL-22
inhibits hepatic gluconeogenesis via the activation of
STAT3 and AMPK without affecting insulin production.
Materials and methods
Materials
Recombinant murine IL-22 protein (rmIL-22) was pur-
chased from R&D system (Minneapolis, MN). All of the
antibodies used for Western blot analysis were pur-
chased from Cell Signaling (Danvers, MA).
Mice
Eight- to ten-week-old male C57BL/6 N mice were pur-
chased from the National Cancer Institute. Liver-specific
IL-22 transgenic mice line 6 (IL-22TG6) on a C57BL/6 N
background were generated as described previously [29].
IL-22TG-6 mice had relatively high serum levels of IL-22
(~600 pg/ml). IL-22 knockout out mice on a C57BL/6
background were kindly provided by Dr. Wenjun Ouyang
(Genentech, San Francisco, CA, USA). All animal study
protocols were reviewed and approved by the Institutional
Animal Care and Use Committee of the National Institute
on Alcohol Abuse and Alcoholism, National Institutes
of Health.
Diet-induced obesity
Eight- to ten-week-old male mice were fed either a con-
trol diet (CD) or a high-fat diet (HFD) for 8 to 12 weeks
or 5 months. The HFD contained 34.0 % fat (60 % of
calories), 26.3 % carbohydrates (20 % of calories), and
26.2 % protein (20 % of calories) as well as fiber, vitamins,
and minerals (D12492, Research Diets, New Brunswick,
NJ, USA). The CD contained 4.3 % fat (10 % of calories)
(D12450B, Research Diets). The mice had free access to
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mice were euthanized and the liver and adipose tissues
(gonadal, retroperitoneal, and subcutaneous) were re-
moved, weighed, and snap-frozen. The adiposity index
was calculated as the combined adipose tissue weight/
carcass body weight × 100 %.
Streptozotocin (STZ)-induced type I diabetes
Mice received 5 daily consecutive injections of 50 mg/kg
STZ (dissolved in citrate buffer, pH 4.5, i.p. injection) in
a volume that did not exceed 50 μl. Blood glucose levels
were assessed after the last injection and then assessed
weakly for 4 weeks.
Glucose tolerance test (GTT), pyruvate tolerance test
(PTT), and insulin tolerance test (ITT)
For the GTT, mice were fasted overnight, and tail vein
blood was collected to measure glucose levels. The mice
were then injected with glucose (2 g/kg i.p.), followed by
the collection of tail vein blood and measurement of
blood glucose levels at various time points. Blood glu-
cose concentrations were measured using a Glucometer
Contour (Bayer HealthCare, Mishawaka, IN, USA). For
the ITT, mice were fasted for 6 h, and tail vein blood
was collected to measure basal blood glucose levels.
Mice were then injected with insulin (0.75 U/kg i.p.,
Eli Lilly), and blood glucose levels were measured at va-
rious time points. For the PTT test, mice were fasted for
16 h and injected with pyruvate (2 g/kg i.p.), and blood
glucose levels were measured at various time points.
Endogenous glucose production measurement in vivo
Basal glucose production was measured in restrained,
conscious mice maintained on HFD for 8 weeks. Four
days before the experiment, mice were anesthetized with
100 mg/kg ketamine and 10 mg/kg xylazine. A catheter
was inserted through a lateral incision on the right side
of the neck into the superior vena cava via the right in-
ternal jugular vein. The catheter was then sutured into
place according to the protocol of MacLeod and Shapiro
[37]. Experiments were started 3 h after fasting. The
basal rates of glucose turnover were measured by con-
tinuous infusion of [3-3H]glucose (2 μCi bolus, then
0.05 μCi/min) for 180 min. Infusions were performed
using microdialysis pumps (CMA 402/Microdialysis,
Acton, MA, USA). Blood samples (20 μl) were collected
via a small nick in the tail vein at 120, 150, 160, 170 and
180 min for the determination of plasma glucose and
plasma [3H] glucose concentrations. An additional 10 μl
of blood were collected at 120 and 180 min to measure
plasma insulin concentrations by RIA (Millipore, St.
Charles, MO, USA). The concentrations of glucose in the
plasma were analyzed via the glucose oxidase method
(YSI 2700 Select, Yellow Springs Instruments, YellowSprings, OH, USA). The determination of plasma [3-3H]
glucose was performed as described previously [38]. The
appearance rates for glucose were calculated as the ratio
of the [3-3H] glucose infusion rate (dpm/min) to the spe-
cific activity of the plasma glucose (dpm/μmol). Data are
presented as average values during the last 30 min of the
experiment.
Glucose production in primary hepatocytes
Glucose production was determined by modified the
protocol described by Foretz M et al. [39]. Briefly, primary
mouse hepatocytes were isolated and plated in a 6-well
collagen I coated plate (Biocoat plate, BD Biosciences,
Bedford, MA) in DMEM containing antibiotics and 10 %
FBS for 4 h, then switched to serum free DMEM with
100 nM dexamethasone (Dex) for 16 h prior to the meas-
urement of glucose production and washed once with
PBS. Cells were then incubated in glucose-free DMEM
containing 10 mM lactate and 1 mM pyruvate with
100 uM Bt2-cAMP (Sigma Aldrich, St. Louis, MO), with
or without IL-22, AKT-inhibitor, or compound C (EMD
Chemicals Inc. Gibbstown, NJ). Glucose production was
detected at 8 h incubation and measured by using 2300
STAT Plus Glucose Analyzer (YSI Life Sciences, Yellow
Springs, OH). The value was normalized to the protein
concentration.
RNA extraction and real time quantitative RT-PCR
RNA was extracted from the liver tissue with Trizol
(Invitrogen, Calsbad, CA) or QIAGEN RNAeasy kit
(QIAGEN, Valencia, CA) according to the manufacturer’s
instructions. mRNA expression of gluconeogenic genes
was determined by real-time quantitative PCR, using a
model 7500 PCR system (Applied Biosystems, Foster City,
CA). Primers used in real-time PCR were described pre-
viously [39].
Western blot analysis
Liver tissue was homogenized in the RIPA Lysis buffer
containing proteinase cocktail, PMSF, and sodium ortho-
vanadate (Santa Cruz Biotechnology, Inc. Santa Cruz,
CA) and grinded by Precellys 24 (Bertin Technologies,
France). To isolate protein extracts from primary hepato-
cytes, cells were washed twice with iced cold PBS, mixed
with RIPA Lysis buffer, and then sonicated on ice for 20 s
prior to collecting protein solution. Western blot analyses
were performed and protein bands were visualized by en-
hanced chemiluminescence reaction (Amersham Pharmacia
Biotech, Piscataway, NJ).
Blood chemistry
Serum ALT levels were measured using chemistry analyzer
(IDEXX Catalyst Dx, IDEXX Laboratories, Westbrook,
ME). Serum insulin levels were determined using an ELISA
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were measured by an ELISA kit (R&D system).
Hepatic triglyceride contents
Chloroform/methanol (2:1) solution was used for lipid
extraction from the total liver. Extracted lipid was then
dissolved in 5 % triton X-100 solution and hepatic trigly-
ceride levels was measured using EnzyChrom™ triglyce-
ride assay kit (BioAssay Systems, Hayward, CA).
Histopathology
For general histological analysis, liver tissues were fixed
in the 10 % neutralized formalin solution and embedded
in the paraffin. Tissues were cut 4-um thickness and
stained with hematoxylin and eosin (H&E). For Oil red
O staining for fat accumulation, frozen liver tissues were
cut for 10 μm sections with cryostat and stained with
pre-warmed Oil Red O solution (Vector Laboratories,
Burlingame, CA) for 10 min, rinsed in water, and then
counterstained with Mayer’s hematoxylin, and analyzed
by light microscopy.
Administration of mice with IL-22 adenovirus
IL-22 adenovirus was made by cloning mouse IL-22 cDNA
(544 bp) into the pENTR/D-TOPO system (Invitrogen),
followed by using Invitrogen Gateway system to perform a
LR reaction with pAd/CMV/V5-DEST to make the ex-
pression vector pAd/CMV/mIL-22. Mice were injected
(intravenously) with adenovirus-IL-22 (2 × 108 pfu) or
adenovirus-empty vector (2 × 108 pfu).
Statistical analysis
Data are expressed as the mean ± SEM. To compare
values obtained from two groups, Student’s t-test was per-
formed. To compare values obtained from three or more
groups, one-way ANOVA was performed followed by
Tukey’s post-hoc test. A value of P < 0.05 was considered
significant.
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